ISRCTN52111708已完成未知
Hepatitis B immunoglobulin (HBIg) withdrawal from combination lamivudine (LAM)/HBIg prophylaxis in liver transplant recipients
niversity of Birmingham (UK)0 个研究点目标入组 120 人开始时间: 2005年10月12日最近更新:
适应症
试验速览
- 阶段
- 未知
- 状态
- 已完成
- 发起方
- 入组人数
- 120
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 性别
- All
入选标准
- •1. Male or female patients 18 to 75 years of age
- •2. Patients with serum HBsAg negativity and HBV DNA negativity (<200 copies/mL as per Roche COBAS AMPLICOR HBV MONITOR)
- •3. Patients have received a liver transplantation and have been successfully treated with lamivudine and HBIg for at least 12 months
- •4. Females of childbearing potential must have a negative urine pregnancy test at screening. Pre-menopausal females who are using effective methods of contraception and who agree to continue to do so for the duration of the study medication dosing and for 30 days after the last dose of study medication will be able to participate. Post-menopausal females will be eligible for enrollment
- •5. Confirmation that sexually active males must be practicing acceptable methods of contraception (vasectomy, condom, monogamous relationship with a female partner who practices an acceptable method of contraception) during the treatment period
- •6. Able to give written informed consent and comply with the requirements of the study
排除标准
- •1. Lactating females or females with a positive pregnancy test
- •2. History of hypersensitivity to HBIg, lamivudine or adefovir dipivoxil. HCV, hepatitis delta virus (HDV), and/or human immunodeficiency virus (HIV) seropositive
- •3. Evidence of active liver disease due to other causes (e.g. Wilson?s disease, hemochromatosis, autoimmune hepatitis, hepatitis C or hepatitis D co-infection, known HIV positivity, alpha-1 antitrypsin deficiency, alcoholic liver disease, obesity-induced liver disease, drug-related liver diseases)
- •4. Previous participation in an investigational trial involving administration of any investigational compound within 3 months prior to the study screening
- •5. Clinically relevant alcohol or drug use or history of alcohol or drug use considered by the investigator to be sufficient to hinder compliance with treatment, follow-up procedures or evaluation of adverse events
- •6. Therapy with nephrotoxic drugs (e.g. aminoglycosides, amphotericin B, vancomycin, cidofovir, foscarnet, cis-platin, pentamidine) or competitors of renal excretion (e.g. probenecid) within 2 months prior to study screening or the expectation that subject will receive these during the course of the study, unless clinically mandated
- •7. The use of antiviral therapy with agents demonstrating potential anti-HBV activity within the previous 3 months (e.g. adefovir dipivoxil, famciclovir, lobucavir, emtricitabine, DAPD, LFMAU, entecavir, ganciclovir, tenofovir or others), other than lamivudine and HBIg
研究者
相似试验
进行中（未招募）
1 期
Hepatitis B immunoglobulins to induce HBsAg clearance in patients with chronic hepatitis BEUCTR2021-005362-18-DEHannover Medical School20
已完成
不适用
HBsAg clearance with pegylated interferon and tenofovir combinatioISRCTN12811193King Faisal Specialist Hospital and Research Centre50
进行中（未招募）
1 期
Treatment withdrawal in patients with hepatitis B virus infection to promote clearance of the virus from the bodyHepatitis B viral infectionMedDRA version: 19.0Level: PTClassification code 10008910Term: Chronic hepatitis BSystem Organ Class: 10021881 - Infections and infestationsMedDRA version: 19.0Level: PTClassification code 10052297Term: Hepatitis B e antigen negativeSystem Organ Class: 10022891 - InvestigationsEUCTR2016-001010-17-GBImperial College, London
进行中（未招募）
2 期
ucleos(t)ide withdrawal in Hepatitis B virus infection (NUC-B)Specialty: Hepatology, Primary sub-specialty: HepatologyUKCRC code/ Disease: Infection/ Viral hepatitisInfections and InfestationsHepatitis BISRCTN84346215Imperial College London240
进行中（未招募）
不适用
An open-label, phase IV, multicentre study to assess the long-term persistence of antibodies against hepatitis B and the immunogenicity and safety study of a single dose hepatitis B (Engerix™-B Kinder) vaccine challenge in adolescents aged 12-13 years, previously primed and boosted in the first two years of life with four doses of GSK Biologicals’ DTPa-HBV-IPV/Hib (Infanrix™ hexa) vaccine.Hepatitis BEUCTR2013-002821-41-DEGlaxoSmithKline Biologicals